A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer

被引：0
|
作者：
Siu, LL
Takimoto, CH
Awada, A
Moore, MJ
Piccart, M
Poulin-Costello, M
Lathia, C
Petrenciuc, O
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA
[3] Inst Jules Bordet, B-1000 Brussels, Belgium
[4] Bayer Inc, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3059
引用
收藏
页码：209S / 209S
页数：1
相关论文
共 50 条
  • [21] Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma:: CALGB 30307
    Janne, P. A.
    Wang, X. F.
    Krug, L. M.
    Hodgson, L.
    Vokes, E. E.
    Kindler, H. L.
    LUNG CANCER, 2006, 54 : S51 - S52
  • [22] Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer
    Richly, D.
    Kupsch, P.
    Passage, K.
    Grubert, M.
    Hilger, R. A.
    Voigtmann, R.
    Schwartz, B.
    Brendel, E.
    Haase, C.
    Strumberg, D.
    ANNALS OF ONCOLOGY, 2004, 15 : 104 - 104
  • [23] Gemcitabine in advanced pancreatic cancer: A phase II trial
    Crino, L
    Mosconi, AM
    Calandri, C
    Corgna, E
    Darwish, S
    Tonato, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1266 - 1266
  • [24] Gemcitabine in advanced pancreatic cancer -: A phase II trial
    Crinò, L
    Mosconi, AM
    Calandri, C
    Corgna, E
    Porrozzi, S
    Chiara, S
    Nobili, MT
    Tonato, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03): : 296 - 298
  • [25] A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid cancers.
    Awada, A
    Hendlisz, A
    Gil, T
    Bleiberg, H
    Bartholomeus, S
    De Valeriola, D
    Dewitte, M
    Coppieters, S
    Moeller, J
    De Becker, D
    Meert, A
    Piccart, M
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3768S
  • [26] Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma.
    Flaherty, KT
    Redlinger, M
    Schuchter, LM
    Lathia, CD
    Weber, BL
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 201S - 201S
  • [27] Phase I trial of gemcitabine and paclitaxel in advanced solid tumors
    Lim, N
    Lara, PN
    Lau, DHM
    Edelman, MJ
    Tanaka, M
    Al-Jazayrly, G
    Houston, J
    Lauder, I
    Gandara, DR
    CANCER INVESTIGATION, 2003, 21 (01) : 7 - 13
  • [28] Phase II study of Sorafenib (BAY 43-9006) in combination with Gemcitabine in recurrent epithelial ovarian cancer - a study of the PMH phase II consortium
    Townsley, C.
    Hirte, H.
    Sharma, S.
    Pond, G.
    Tinker, L.
    Afinec, A.
    Wright, J.
    Oza, A. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 272 - 272
  • [29] A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer
    Yamada, Yasuhide
    Minami, Hironobu
    Fuse, Nozomu
    Ohtsu, Atsushi
    Kato, Ken
    Kiyota, Naomi
    Shimada, Yasushiro
    Doi, Toshihiko
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Fujiwara, Yutaka
    Ito, Yuichiro
    Mera, Kiyomi
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [30] Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    Awada, A
    Hendlisz, A
    Gil, T
    Bartholomeus, S
    Mano, M
    de Valeriola, D
    Strumberg, D
    Brendel, E
    Haase, CG
    Schwartz, B
    Piccart, M
    BRITISH JOURNAL OF CANCER, 2005, 92 (10) : 1855 - 1861
12345